Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

(2015) Hirotsugu Kenmotsu et al.   CANCER SCIENCE

Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy

(2015) D. Cardinale et al.   CIRCULATION

Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity

(2015) Eric S. Christenson et al.   CLINICAL BIOCHEMISTRY

Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma

(2015) E. Wilson Grandin et al.   JOURNAL OF CARDIAC FAILURE

Tyrosine Kinase Inhibitor–Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

(2015) Javid J. Moslehi et al.   JOURNAL OF CLINICAL ONCOLOGY

Vascular and Metabolic Implications of Novel Targeted Cancer Therapies

(2015) Weijuan Li et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Erratum: Cardiotoxicity of anticancer treatments

(2015) Michael S. Ewer et al.   Nature Reviews Cardiology

Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib

(2015) S Atrash et al.   Blood Cancer Journal

Cardiotoxicity due to Chemotherapy: the Role of Biomarkers

(2015) Patrick L. Stevens et al.   Current Cardiology Reports

Cancer and Cardiovascular Disease: The Complex Labyrinth

(2015) Susan Dent et al.   Journal of Oncology

Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms

(2015) Neil K. Taunk et al.   Frontiers in Oncology

Clinical guide SEOM on venous thromboembolism in cancer patients

(2014) A. J. Muñoz Martín et al.   Clinical & Translational Oncology

Cardiovascular disease after cancer therapy

(2014) Berthe M.P. Aleman et al.   EJC SUPPLEMENTS

Protective effects of spironolactone against anthracycline-induced cardiomyopathy

(2014) Mahmut Akpek et al.   EUROPEAN JOURNAL OF HEART FAILURE

Cancer Therapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis

(2014) Akanksha Thakur et al.   JOURNAL OF CARDIAC FAILURE

Aging and Risk of Severe, Disabling, Life-Threatening, and Fatal Events in the Childhood Cancer Survivor Study

(2014) Gregory T. Armstrong et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy

(2014) Paaladinesh Thavendiranathan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging

(2014) Juan Carlos Plana et al.   JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY

Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies

(2014) Virginia Shalkey Hahn et al.   Journal of the American Heart Association

Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist

(2013) Cristian Mornoş et al.   CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY

Cardioprotective Effect of β-Adrenoceptor Blockade in Patients With Breast Cancer Undergoing Chemotherapy

(2013) Sinziana Seicean et al.   Circulation-Heart Failure

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

(2013) Daniel Castellano et al.   EUROPEAN JOURNAL OF CANCER

Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis

(2013) Kashif Kalam et al.   EUROPEAN JOURNAL OF CANCER

Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis

(2013) T Funakoshi et al.   JOURNAL OF HUMAN HYPERTENSION

Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies

(2013) Xavier Bosch et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Insights Into Onco-Cardiology

(2013) Dimitrios Farmakis et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Early Increases in Multiple Biomarkers Predict Subsequent Cardiotoxicity in Patients With Breast Cancer Treated With Doxorubicin, Taxanes, and Trastuzumab

(2013) Bonnie Ky et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

(2013) Aron Goldhirsch et al.   LANCET

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

(2013) T D Kim et al.   LEUKEMIA

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

(2013) F J Giles et al.   LEUKEMIA

Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer

(2013) Sarah C. Darby et al.   NEW ENGLAND JOURNAL OF MEDICINE

Low to Moderate Dose Anthracycline-Based Chemotherapy Is Associated With Early Noninvasive Imaging Evidence of Subclinical Cardiovascular Disease

(2013) Brandon C. Drafts et al.   JACC-Cardiovascular Imaging

Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection

(2013) K. Negishi et al.   European Heart Journal-Cardiovascular Imaging

Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications

(2013) Shahzeena Aslam et al.   Therapeutic Advances in Medical Oncology

Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study

(2013) Kathy H. Fraeman et al.   International Journal of Hypertension

Comparison of Three-Year Outcomes After Primary Percutaneous Coronary Intervention in Patients With Left Ventricular Ejection Fraction

(2012) Benoit Daneault et al.   AMERICAN JOURNAL OF CARDIOLOGY

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines

(2012) G. Curigliano et al.   ANNALS OF ONCOLOGY

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib‡

(2012) S. George et al.   ANNALS OF ONCOLOGY

Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection

(2012) A Dewdney et al.   BRITISH JOURNAL OF CANCER

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Rationale and Design of the Prevention of Cardiac Dysfunction during an Adjuvant Breast Cancer Therapy (PRADA) Trial

(2012) Siri Lagethon Heck et al.   CARDIOLOGY

Pulmonary Arterial Hypertension in Patients Treated by Dasatinib

(2012) David Montani et al.   CIRCULATION

Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab

(2012) Heloisa Sawaya et al.   Circulation-Cardiovascular Imaging

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents

(2012) P. Larochelle et al.   Current Oncology

Cancer drugs and the heart: importance and management

(2012) T. M. Suter et al.   EUROPEAN HEART JOURNAL

Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study

(2012) Mehmet G. Kaya et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes

(2012) Steven E. Lipshultz et al.   JOURNAL OF CLINICAL ONCOLOGY

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2012) Edward H. Romond et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy

(2012) Sinziana Seicean et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

(2012) Jersey Chen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and Volumes

(2012) Paaladinesh Thavendiranathan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

(2012) E. J. A. Bowles et al.   JNCI-Journal of the National Cancer Institute

Identification of the molecular basis of doxorubicin-induced cardiotoxicity

(2012) Sui Zhang et al.   NATURE MEDICINE

Anthracycline-Induced Cardiotoxicity: Cardiac Monitoring by Continuous Wave-Doppler Ultrasound Cardiac Output Monitoring and Correlation to Echocardiography

(2012) Sandra Geiger et al.   ONKOLOGIE

Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study

(2012) A. M. C. Mavinkurve-Groothuis et al.   European Heart Journal-Cardiovascular Imaging

Early Detection and Prediction of Cardiotoxicity in Chemotherapy-Treated Patients

(2011) Heloisa Sawaya et al.   AMERICAN JOURNAL OF CARDIOLOGY

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

(2011) D. Lenihan et al.   ANNALS OF ONCOLOGY

Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101 - Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI

(2011) Edith Pituskin et al.   BMC CANCER

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

(2011) Claudia Lebedinsky et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib

(2011) P. G. Morris et al.   CLINICAL CANCER RESEARCH

Role of biomarkers in cardioncology

(2011) Daniela Cardinale et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31

(2011) Edith A. Perez et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy

(2011) Zeydin Acar et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Utility of Cardiac Biomarkers, Tissue Velocity and Strain Imaging, and Cardiac Magnetic Resonance Imaging in Predicting Early Left Ventricular Dysfunction in Patients With Human Epidermal Growth Factor Receptor II–Positive Breast Cancer Treated With Adjuvant Trastuzumab Therapy

(2011) Nazanin Fallah-Rad et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

(2011) Thomas Force et al.   NATURE REVIEWS DRUG DISCOVERY

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

(2011) Dennis Slamon et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Observational Study of Bevacizumab-Induced Hypertension as a Clinical Biomarker of Antitumor Activity

(2011) O. Mir et al.   ONCOLOGIST

Biomarker Approach to the Detection and Cardioprotective Strategies During Anthracycline Chemotherapy

(2011) Bonnie Ky et al.   Heart Failure Clinics

Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment

(2010) Christian Cadeddu et al.   AMERICAN HEART JOURNAL

Cardiovascular complications of conventional and targeted adjuvant breast cancer therapy

(2010) N. Harbeck et al.   ANNALS OF ONCOLOGY

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

(2010) Lesley A Smith et al.   BMC CANCER

Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics

(2010) Hui Cheng et al.   CIRCULATION RESEARCH

European Society of Cardiology Heart Failure Association Standards for delivering heart failure care

(2010) Theresa A. McDonagh et al.   EUROPEAN JOURNAL OF HEART FAILURE

Radiation Dose–Volume Effects in the Heart

(2010) Giovanna Gagliardi et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress

(2010) Vishnu Chintalgattu et al.   JOURNAL OF CLINICAL INVESTIGATION

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial

(2010) Marion Procter et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation

(2010) Daniela Cardinale et al.   JOURNAL OF CLINICAL ONCOLOGY

Anthracycline-Induced Cardiomyopathy

(2010) Daniela Cardinale et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data

(2010) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial

(2010) Steven E Lipshultz et al.   LANCET ONCOLOGY

Declining Death Rates Reflect Progress against Cancer

(2010) Ahmedin Jemal et al.   PLoS One

Prolonged QTc Interval in Cancer Therapeutic Drug Development: Defining Arrhythmic Risk in Malignancy

(2010) Joanna M. Brell   PROGRESS IN CARDIOVASCULAR DISEASES

Capecitabine-induced cardiotoxicity mimicking myocardial infarction

(2010) T. Şentürk et al.   Netherlands Heart Journal

Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk

(2009) P. J. Barrett-Lee et al.   ANNALS OF ONCOLOGY

Pretreatment with Statin Attenuates the Cardiotoxicity of Doxorubicin in Mice

(2009) A. Riad et al.   CANCER RESEARCH

Introducing a new entity: chemotherapy-induced arrhythmia

(2009) M. Guglin et al.   EUROPACE

Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography

(2009) S. F. Nagueh et al.   European Journal of Echocardiography

Effective Strategies for Management of Hypertension After Vascular Endothelial Growth Factor Signaling Inhibition Therapy: Results From a Phase II Randomized, Factorial, Double-Blind Study of Cediranib in Patients With Advanced Solid Tumors

(2009) Marlies H.G. Langenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiovascular Complications of Cancer Therapy

(2009) Edward T.H. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical Correlation between Brain Natriutetic Peptide and Anthracyclin-induced Cardiac Toxicity

(2009) Ho Sup Lee et al.   Cancer Research and Treatment

Development and validation of a predictive model for chemotherapy-associated thrombosis

(2008) A. A. Khorana et al.   BLOOD

Cardiac Management During Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group

(2008) John Mackey   Current Oncology

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY

Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground?

(2008) Michael S. Ewer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants

(2008) Martee L. Hensley et al.   JOURNAL OF CLINICAL ONCOLOGY